Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline-Reference-Cited by-同舟云学术

Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline

Published:2022-11-10 Issue:11 Volume:14 Page:2488
ISSN:1999-4915
Container-title:Viruses
language:en
Short-container-title:Viruses

Author:

Focosi Daniele^ORCID,Maggi Fabrizio^ORCID

Abstract

The wild-type SARS-CoV-2 Spike-based vaccines authorized so far have reduced COVID-19 severity, but periodic boosts are required to counteract the decline in immunity. An accelerated rate of immune escape to vaccine-elicited immunity has been associated with Spike protein antigenic shifts, as seen in the Omicron variant of concern and its sublineages, demanding the development of Omicron Spike-based vaccines. Herein, we review the evidence in animal models and topline results from ongoing clinical trials with such updated vaccines, discussing the pros and cons for their deployment.

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Link

https://www.mdpi.com/1999-4915/14/11/2488/pdf

Reference65 articles.

1. Evidence for a mouse origin of the SARS-CoV-2 Omicron variant;J. Genet. Genom.,2021

2. Bentley, E.G., Kirby, A., Sharma, P., Kipar, A., Mega, D.F., Bramwell, C., Penrice-Randal, R., Prince, T., Brown, J.C., and Zhou, J. (2021). SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19. BioRxiv.

3. Suryawanshi, R.K., Chen, I.P., Ma, T., Syed, A.M., Simoneau, C.R., Ciling, A., Khalid, M.M., Sreekumar, B., Chen, P.-Y., and George, A.F. (2022). Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination. medRxiv.

4. (2022, June 27). Pfizer and BioNTech Provide Update on Rolling Submission to European Medicines Agency for a Potential Variant-Adapted Vaccine. Available online: https://www.pfizer.com/news/announcements/pfizer-and-biontech-provide-update-rolling-submission-european-medicines-agency.

5. (2022, June 27). Start of Rolling Review for Adapted Comirnaty COVID-19 Vaccine. Available online: https://www.ema.europa.eu/en/news/start-rolling-review-adapted-comirnaty-COVID-19-vaccine.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases;Cell Communication and Signaling;2023-05-15

2. Pandemic Fatigue in Japan: Factors Affecting the Declining COVID-19 Preventive Measures;Sustainability;2023-04-04

3. Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge;International Journal of Molecular Sciences;2023-01-23

4. From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses;Vaccines;2023-01-02

5. Convergent evolution in SARS-CoV-2 Spike creates a variant soup that causes new COVID-19 waves;2022-12-05